亚脂蛋白A1和高密度脂蛋白通过结合SR-B1限制低密度脂蛋白转细胞化
Karen Y Y Fung1, Tse Wing Winnie Ho2, Zizhen Xu3
1Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada; Keenan Research Centre, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada.
Journal of lipid research
|March 13, 2024
概括
高密度脂蛋白 (HDL) 可能通过与低密度脂蛋白 (LDL) 竞争与清洁剂受体B1 (SR-B1) 结合,从而减少动脉中的LDL沉积,从而防止动脉硬化.
科学领域:
- 心血管生物学 心血管生物学
- 脂质代谢 脂质代谢是什么
- 动脉样硬化研究 动脉样硬化研究
背景情况:
- 动脉样硬化涉及低密度脂蛋白 (LDL) 在动脉中的沉积和氧化,导致阻塞.
- 通过内皮细胞的LDL转细胞是动脉样硬化发展的关键步骤.
- 高密度脂蛋白 (HDL) 据信可以提供对动脉样硬化的保护.
研究的目的:
- 为了研究HDL的组成部分阿波利波蛋白A1 (APOA1) 是否可以与LDL竞争拾尸体受体B1 (SR-B1) 的结合.
- 为了确定HDL或APOA1能否抑制LDL转细胞和随后在动脉壁中的沉积.
主要方法:
- 使用冠状动脉内皮细胞进行体外研究,以量化光LDL内化和转细胞.
- 微尺度热泳和亲和度捕获试验,以评估SR-B1和APOA1.1之间的相互作用.
- 在雄性小鼠体内实验,以评估增加的HDL或APOA1水平对LDL沉积的影响.
主要成果:
- 发现SR-B1和APOA1相互作用,在APOA1-米兰变种中观察到增强的结合.
- 在小鼠中增加的HDL水平减少了光LDL在主动脉中的急性沉积.
- 野生型APOA1和APOA1-Milano都抑制了LDL沉积,而APOA1-Milano显示出更强大的效果.
结论:
- HDL,通过APOA1,可以通过竞争SR-B1结合来限制LDL转细胞化.
- 这种竞争可能会减少LDL在亚动脉空间中的沉积,从而促进HDL的动脉保护作用.
- 与野生型APOA1.1相比,APOA1-Milano对LDL沉积具有更强的抑制作用.
相关概念视频
Receptor-mediated Endocytosis
104.4K
Overview
104.4K
Drug Binding to Blood Components
148
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
148
Regulation of Nuclear Protein Sorting
2.4K
Nuclear protein sorting regulates nucleus composition and gene expression, crucial for determining the fate of a eukaryotic cell. Hence, the entry and exit of molecules across the nuclear envelope is a tightly controlled process. Nuclear protein sorting can be inhibited by one of the following ways: 1) masking cargo signal sequences, 2) modifying the nuclear receptor's affinity for cargo, 3) controlling the nuclear pore size, 4) retaining the cargo during its transit to the cytosol or the...
2.4K
Factors Affecting Protein-Drug Binding: Drug-Related Factors
99
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
99
Factors Affecting Protein-Drug Binding: Protein-Related Factors
156
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
156
Drug Distribution: Plasma Protein Binding
5.6K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
5.6K


